Renal cell carcinoma with central nervous system demyelination caused by nivolumab

INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65‐year‐old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain‐enhanced magnetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Toshiki, Yamamoto, Yoshiyuki, Okuda, Yohei, Asakura, Toshihisa, Hatano, Koji, Nakai, Yasutomo, Nakayama, Masashi, Kakimoto, Ken‐ichi, Sugai, Fuminobu, Nishimura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784733/
https://www.ncbi.nlm.nih.gov/pubmed/33426497
http://dx.doi.org/10.1002/iju5.12234
Descripción
Sumario:INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65‐year‐old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain‐enhanced magnetic resonance imaging revealed multiple lesions with partial contrast effects in the cerebral white matter. We tentatively diagnosed demyelination caused by nivolumab, and performed steroid pulse therapy twice. After that, his symptoms improved. For the next 2 years, his symptoms did not recur, nor did his cancer progress. CONCLUSION: Demyelination caused by immune checkpoint inhibitors can be fatal and requires early diagnosis and treatment.

Ejemplares similares